A phase III, multicenter, double-blind, randomized, placebo-controlled trial of CSL 112 in acute coronary syndrome patients

Trial Profile

A phase III, multicenter, double-blind, randomized, placebo-controlled trial of CSL 112 in acute coronary syndrome patients

Planning
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs CSL 112 (Primary)
  • Indications Acute coronary syndromes; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms AEGIS-II
  • Sponsors CSL Behring
  • Most Recent Events

    • 06 Dec 2017 New trial record
    • 04 Dec 2017 According to a CSL Behring media release, this trial is expected to complete over a four-year period, with patient enrollment beginning in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top